Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer : the key role of histopathology. Evidence from an international multicentre prospective study
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
INTRODUCTION: [18F]Fluoroestradiol ([18F]FES) PET/CT has been proposed as a tool for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) non-invasively across all disease localizations. However, its diagnostic potential in terms of the detection rate (DR) of metastases is unclear. In this study, we pitted this method against [18F]FDG PET/CT and tried to identify predictors of the diagnostic superiority of the [18F] FES-based method.
MATERIALS AND METHODS: From a multicentre database, we enrolled all patients with metastatic BC who had undergone both [18F]FES PET/CT and [18F]FDG PET/CT. Two readers assessed both images independently and used a patient-based (PBA) and lesion-based analysis (LBA) to calculate the DR. Pathology-related and clinical factors were tested as predictors of [18F]FES PET/CT superiority using a multivariate model.
RESULTS: 92 patients, bearing a total of 2678 metastases, were enrolled. On PBA, the DR of [18F]FDG and [18F]FES PET/CT was 97% and 86%, respectively (p = 0.018). On LBA, the [18F]FES method proved more sensitive than [18F]FDG PET/CT in lymph nodes, bone, lung and soft tissue (p < 0.01). This greater sensitivity was associated with lobular histology, both on PBA (Odds Ratio (OR) 3.4, 95%CI 1.0-12.3) and on LBA (OR 4.4, 95%CI 1.2-16.1 for lymph node metastases and OR 3.29, 95%CI 1.1-10.2 for bone localizations).
CONCLUSIONS: The overall DR of [18F]FES PET/CT appears to be lower than that of [18F]FDG PET/CT on PBA. However, the [18F]FES method, if positive, can identify more lesions than [18F]FDG at most sites. The higher sensitivity of [18F]FES PET/CT was associated with lobular histology.
| Errataetall: |
CommentOn: Mol Imaging Biol. 2014 Jun;16(3):431-40. - PMID 24170452 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine and molecular imaging - 50(2023), 8 vom: 01. Juli, Seite 2477-2485 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bottoni, Gianluca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 01.01.2024 published: Print-Electronic CommentOn: Mol Imaging Biol. 2014 Jun;16(3):431-40. - PMID 24170452 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00259-023-06173-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353848832 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353848832 | ||
| 003 | DE-627 | ||
| 005 | 20240108140702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-023-06173-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM353848832 | ||
| 035 | |a (NLM)36879065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bottoni, Gianluca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer |b the key role of histopathology. Evidence from an international multicentre prospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 01.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Mol Imaging Biol. 2014 Jun;16(3):431-40. - PMID 24170452 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a INTRODUCTION: [18F]Fluoroestradiol ([18F]FES) PET/CT has been proposed as a tool for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) non-invasively across all disease localizations. However, its diagnostic potential in terms of the detection rate (DR) of metastases is unclear. In this study, we pitted this method against [18F]FDG PET/CT and tried to identify predictors of the diagnostic superiority of the [18F] FES-based method | ||
| 520 | |a MATERIALS AND METHODS: From a multicentre database, we enrolled all patients with metastatic BC who had undergone both [18F]FES PET/CT and [18F]FDG PET/CT. Two readers assessed both images independently and used a patient-based (PBA) and lesion-based analysis (LBA) to calculate the DR. Pathology-related and clinical factors were tested as predictors of [18F]FES PET/CT superiority using a multivariate model | ||
| 520 | |a RESULTS: 92 patients, bearing a total of 2678 metastases, were enrolled. On PBA, the DR of [18F]FDG and [18F]FES PET/CT was 97% and 86%, respectively (p = 0.018). On LBA, the [18F]FES method proved more sensitive than [18F]FDG PET/CT in lymph nodes, bone, lung and soft tissue (p < 0.01). This greater sensitivity was associated with lobular histology, both on PBA (Odds Ratio (OR) 3.4, 95%CI 1.0-12.3) and on LBA (OR 4.4, 95%CI 1.2-16.1 for lymph node metastases and OR 3.29, 95%CI 1.1-10.2 for bone localizations) | ||
| 520 | |a CONCLUSIONS: The overall DR of [18F]FES PET/CT appears to be lower than that of [18F]FDG PET/CT on PBA. However, the [18F]FES method, if positive, can identify more lesions than [18F]FDG at most sites. The higher sensitivity of [18F]FES PET/CT was associated with lobular histology | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Estrogen receptor | |
| 650 | 4 | |a FDG | |
| 650 | 4 | |a FES | |
| 650 | 4 | |a Lobular histology | |
| 650 | 4 | |a Nuclear medicine | |
| 650 | 4 | |a PET | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Estradiol |2 NLM | |
| 650 | 7 | |a 4TI98Z838E |2 NLM | |
| 700 | 1 | |a Fiz, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Puntoni, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Matteucci, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a DeCensi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Nanni, Oriana |e verfasserin |4 aut | |
| 700 | 1 | |a Brain, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Alberini, Jean Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Dib, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Sacchetti, Gianmauro |e verfasserin |4 aut | |
| 700 | 1 | |a Trimboli, Pierpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Treglia, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Sola, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Piccardo, Arnoldo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d 2002 |g 50(2023), 8 vom: 01. Juli, Seite 2477-2485 |w (DE-627)NLM116957360 |x 1619-7089 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:8 |g day:01 |g month:07 |g pages:2477-2485 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-023-06173-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 8 |b 01 |c 07 |h 2477-2485 | ||